Noticias

Noticias

  • Título: FDA Grants Premarket Approval for Silk Road Medical's ENROUTE® Transcarotid Stent System
  • Fecha: 19-05-2015

  • SUNNYVALE, Calif., May 19, 2015 /PRNewswire/ -- Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the company has received Premarket Approval (PMA) from the United States Food & Drug Administration (FDA) for the ENROUTE Transcarotid Stent System. The ENROUTE Transcarotid Stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting.

    The ENROUTE Transcarotid Stent is indicated for use in High Surgical Risk patients and is intended to be used in conjunction with Silk Road Medical's ENROUTE Transcarotid Neuroprotection System (NPS), which recently received 510(k) clearance by the FDA. Together the ENROUTE Transcarotid NPS and Stent System enables a novel hybrid procedure called TransCarotid Artery Revascularization (TCAR), which combines surgical principles of neuroprotection with a less invasive stenting procedure. The ENROUTE Transcarotid NPS is a first in class system used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.

    The ENROUTE Transcarotid Stent was developed pursuant to a license with Cordis Corporation and leverages the micromesh design and long term durability of the Cordis PRECISE® Carotid Stent that was clinically proven in tens of thousands of patients across multiple clinical trials including SAPPHIRE, CASES-PMS and SAPPHIRE Worldwide. The ENROUTE Transcarotid Stent has a shorter delivery system optimized for transcarotid access and was recently trialed by leading European physicians.

    "TCAR allows us to avoid potential stroke hazards at the aortic arch while placing a stent under robust flow reversal which simulates the superb neuroprotection of CEA," commented Prof. Dr. med. Ralf Kolvenbach, Chief of Vascular Surgery at Augusta Hospital, Dusseldorf Catholic Hospital Group. "With the ENROUTE Transcarotid Stent we now have a dedicated, ergonomic stent platform for TCAR that combines the control afforded by transcarotid access with the stent's visibility under x-ray, allowing for confident, precise stent placement."

    The U.S. FDA PMA was based in part on data collected from a subset (52) of 141 High Surgical Risk patients in the ROADSTER study who were treated with the Cordis PRECISE PRO RX® Stent System and the ENROUTE Transcarotid NPS. Technical success was 100% (52/52) and the Major Adverse Event (MAE) rate at 30 days was 1.9% consisting of a single minor stroke, comparable to the overall ROADSTER results of 3.5% MAE and 1.4% stroke.

    "TCAR was led and inspired by vascular specialists looking for ways to treat their patients with safer and more effective methods. The ENROUTE Transcarotid NPS and Stent System is an innovation that will push forward the field of carotid revascularization. Severe carotid artery stenosis is one of the last frontiers in vascular disease that is still treated primarily by an open surgical approach and we look forward to bringing our less invasive, surgically-inspired ENROUTE Transcarotid System to market for vascular specialists and their patients," said Lucas Buchanan, Executive Vice President of Corporate Development and Commercialization.

    About Silk Road Medical
    Silk Road Medical, Inc. is a private company located in Sunnyvale, CA, that develops and manufactures less-invasive medical devices intended to improve the treatment of intra and extracranial cerebrovascular disease through proprietary transcarotid therapies. Detailed information about Silk Road Medical can be found at www.silkroadmed.com.

    Silk Road and ENROUTE are registered trademarks of Silk Road Medical, Inc.
    CORDIS®, PRECISE®, and PRECISE PRO RX® are all registered trademarks of Cordis Corporation. Third party trademarks used herein are trademarks of their respective owners.

    Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Please refer to package insert for indications, contraindications, warnings, precautions, and instructions for use.


    SOURCE Silk Road Medical, Inc.



    RELATED LINKS

    http://www.silkroadmed.com



  • Fuente: endovascular.es